FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382025296> ?p ?o ?g. }

• W4382025296 abstract "Abstract Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, demonstrated efficacy in adults with severe alopecia areata (AA) over 36 weeks in two phase III, randomized, double-blind, placebo-controlled trials, BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259). Using integrated data from the long-term extension periods of both trials, we report treatment response to baricitinib by the AA severity subgroup based on the Severity of Alopecia Tool (SALT) score over 52 weeks. Patients randomized to baricitinib at baseline (n = 855) retained their treatment allocation (2 mg/4 mg) through to week 52 in both trials and were included in week 52 analyses; placebo nonresponders were rescued at week 36. Severity of AA at baseline was defined as severe (SALT score 50–94) or very severe (SALT score 95–100). Key inclusion criteria were SALT score ≥ 50, current AA episode lasting &gt; 6 months to &lt; 8 years without spontaneous improvement within 6 months prior to screening, and no previous inadequate response to oral JAK inhibitors. Efficacy endpoints included the proportion of patients achieving a SALT score ≤ 20 and the proportion of patients achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow/Eyelash Hair Loss™ 0,1 (no, minimal gaps) with ≥ 2-point improvement from baseline among patients with baseline scores 2,3 (significant gaps, no notable eyebrows/eyelashes). Analyses were presented descriptively for each subgroup up to week 52. Nonresponder imputation was used for missing data. Data collected after permanent study drug discontinuation or at remote visits due to the COVID-19 pandemic were excluded. In total, 1200 patients were enrolled (BRAVE-AA1, n = 654; BRAVE-AA2, n = 546). At baseline, the overall mean (SD) age was 37.5 (12.9) years; 60.7% were female and 46.8% and 53.2% of patients had severe and very severe AA, respectively. At week 52, a SALT score ≤ 20 was achieved by 36.1% and 51.2% of patients on baricitinib 2 mg and baricitinib 4 mg, respectively, with severe AA and 12.4% and 27.7% of patients on baricitinib 2 mg and baricitinib 4 mg, respectively, with very severe AA. Eyebrow/Eyelash Hair Loss™ scores 0,1 with ≥ 2-point improvement from baseline at week 52 were achieved by 19.4% and 26.0% (baricitinib 2 mg) and 37.5% and 38.5% (baricitinib 4 mg) of patients with severe AA and 24.3% and 25.3% (baricitinib 2 mg) and 47.6% and 48.1% (baricitinib 4 mg) of patients with very severe AA. Following 52 weeks of treatment with both baricitinib doses, clinical responses of SALT score ≤ 20 were observed both in patients with severe and very severe AA. Proportions of patients achieving full coverage or minimal gaps in eyebrows and eyelashes were similar at week 52, regardless of scalp hair-loss severity. Funding sources: Eli Lilly and Company." @default.
• W4382025296 created "2023-06-27" @default.
• W4382025296 creator A5009079207 @default.
• W4382025296 creator A5013384712 @default.
• W4382025296 creator A5014659729 @default.
• W4382025296 creator A5038782110 @default.
• W4382025296 creator A5044187376 @default.
• W4382025296 creator A5054489956 @default.
• W4382025296 creator A5065337670 @default.
• W4382025296 creator A5072554320 @default.
• W4382025296 date "2023-06-01" @default.
• W4382025296 modified "2023-09-24" @default.
• W4382025296 title "P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2" @default.
• W4382025296 doi "https://doi.org/10.1093/bjd/ljad113.092" @default.
• W4382025296 hasPublicationYear "2023" @default.
• W4382025296 type Work @default.
• W4382025296 citedByCount "0" @default.
• W4382025296 crossrefType "journal-article" @default.
• W4382025296 hasAuthorship W4382025296A5009079207 @default.
• W4382025296 hasAuthorship W4382025296A5013384712 @default.
• W4382025296 hasAuthorship W4382025296A5014659729 @default.
• W4382025296 hasAuthorship W4382025296A5038782110 @default.
• W4382025296 hasAuthorship W4382025296A5044187376 @default.
• W4382025296 hasAuthorship W4382025296A5054489956 @default.
• W4382025296 hasAuthorship W4382025296A5065337670 @default.
• W4382025296 hasAuthorship W4382025296A5072554320 @default.
• W4382025296 hasBestOaLocation W43820252961 @default.
• W4382025296 hasConcept C126322002 @default.
• W4382025296 hasConcept C142724271 @default.
• W4382025296 hasConcept C16005928 @default.
• W4382025296 hasConcept C168563851 @default.
• W4382025296 hasConcept C204787440 @default.
• W4382025296 hasConcept C27081682 @default.
• W4382025296 hasConcept C2777524370 @default.
• W4382025296 hasConcept C2778715236 @default.
• W4382025296 hasConcept C71924100 @default.
• W4382025296 hasConceptScore W4382025296C126322002 @default.
• W4382025296 hasConceptScore W4382025296C142724271 @default.
• W4382025296 hasConceptScore W4382025296C16005928 @default.
• W4382025296 hasConceptScore W4382025296C168563851 @default.
• W4382025296 hasConceptScore W4382025296C204787440 @default.
• W4382025296 hasConceptScore W4382025296C27081682 @default.
• W4382025296 hasConceptScore W4382025296C2777524370 @default.
• W4382025296 hasConceptScore W4382025296C2778715236 @default.
• W4382025296 hasConceptScore W4382025296C71924100 @default.
• W4382025296 hasIssue "Supplement_4" @default.
• W4382025296 hasLocation W43820252961 @default.
• W4382025296 hasOpenAccess W4382025296 @default.
• W4382025296 hasPrimaryLocation W43820252961 @default.
• W4382025296 hasRelatedWork W2044090606 @default.
• W4382025296 hasRelatedWork W2068981453 @default.
• W4382025296 hasRelatedWork W2121750057 @default.
• W4382025296 hasRelatedWork W2404906068 @default.
• W4382025296 hasRelatedWork W2440286091 @default.
• W4382025296 hasRelatedWork W2658590342 @default.
• W4382025296 hasRelatedWork W2766455916 @default.
• W4382025296 hasRelatedWork W2766844642 @default.
• W4382025296 hasRelatedWork W2941516307 @default.
• W4382025296 hasRelatedWork W3166178439 @default.
• W4382025296 hasVolume "188" @default.
• W4382025296 isParatext "false" @default.
• W4382025296 isRetracted "false" @default.
• W4382025296 workType "article" @default.